Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Protagonist Therapeutics ( (PTGX) ) has provided an update.
At the Annual Meeting, Protagonist Therapeutics‘ stockholders voted on three key proposals. The first proposal involved electing two Class III directors, Harold E. Selick, Ph.D., and Bryan Giraudo, to serve until the 2028 Annual Meeting, both of whom were elected. The second proposal, regarding the approval of executive compensation, was passed. The third proposal, ratifying Ernst & Young LLP as the company’s independent auditor for the fiscal year ending December 31, 2025, was also approved.
The most recent analyst rating on (PTGX) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Protagonist Therapeutics stock, see the PTGX Stock Forecast page.
Spark’s Take on PTGX Stock
According to Spark, TipRanks’ AI Analyst, PTGX is a Neutral.
Protagonist Therapeutics’ overall score is driven by a mix of financial performance and technical analysis. The positive trend in stock price is offset by financial instability, high valuation metrics, and the absence of consistent revenue growth.
To see Spark’s full report on PTGX stock, click here.
More about Protagonist Therapeutics
Average Trading Volume: 1,022,413
Technical Sentiment Signal: Buy
Current Market Cap: $3.37B
For a thorough assessment of PTGX stock, go to TipRanks’ Stock Analysis page.